215 related articles for article (PubMed ID: 18622632)
1. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome.
Dorresteijn EM; Kist-van Holthe JE; Levtchenko EN; Nauta J; Hop WC; van der Heijden AJ
Pediatr Nephrol; 2008 Nov; 23(11):2013-20. PubMed ID: 18622632
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome of Japanese children with complicated minimal change nephrotic syndrome treated with mycophenolate mofetil after cyclosporine.
Fujinaga S; Hirano D; Nishino T; Umeda C; Watanabe Y; Nakagawa M
Pediatr Nephrol; 2019 Nov; 34(11):2417-2421. PubMed ID: 31435725
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab.
Fujinaga S; Someya T; Watanabe T; Ito A; Ohtomo Y; Shimizu T; Kaneko K
Eur J Pediatr; 2013 Apr; 172(4):513-8. PubMed ID: 23271494
[TBL] [Abstract][Full Text] [Related]
4. Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome.
Gellermann J; Ehrich JH; Querfeld U
Nephrol Dial Transplant; 2012 May; 27(5):1970-8. PubMed ID: 21976740
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome.
Gellermann J; Weber L; Pape L; Tönshoff B; Hoyer P; Querfeld U;
J Am Soc Nephrol; 2013 Oct; 24(10):1689-97. PubMed ID: 23813218
[TBL] [Abstract][Full Text] [Related]
6. Serum suPAR levels are modulated by immunosuppressive therapy of minimal change nephrotic syndrome.
Gellermann J; Schaefer F; Querfeld U
Pediatr Nephrol; 2014 Dec; 29(12):2411-4. PubMed ID: 25129204
[TBL] [Abstract][Full Text] [Related]
7. Three year outcome of childhood idiopathic nephrotic syndrome under a unified immunosuppressive protocol.
Hibino S; Uemura O; Nagai T; Yamakawa S; Iwata N; Ito H; Nakano M; Tanaka K
Pediatr Int; 2015; 57(1):85-91. PubMed ID: 25225083
[TBL] [Abstract][Full Text] [Related]
8. [Mycophenolate mofetil in treatment of childhood nephrotic syndrome--preliminary report].
Kwinta-Rybicka J; Wilkosz K; Wierzchowska-Słowiacze EK; Ogarek I; Moczulska A; Stec Z; Pełkowska A; Sancewicz-Pach K; Pietrzyk JA
Przegl Lek; 2006; 63 Suppl 3():44-8. PubMed ID: 16898486
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome.
Wang J; Mao J; Chen J; Fu H; Shen H; Zhu X; Liu A; Shu Q; Du L
Nephrology (Carlton); 2016 Jan; 21(1):21-7. PubMed ID: 26697959
[TBL] [Abstract][Full Text] [Related]
10. A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome.
Fujinaga S; Ohtomo Y; Umino D; Takemoto M; Shimizu T; Yamashiro Y; Kaneko K
Pediatr Nephrol; 2007 Jan; 22(1):71-6. PubMed ID: 17086405
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of therapeutic effects of prednisone combined with mycophenolate mofetil versus cyclosporin A in children with steroid-resistant nephrotic syndrome].
Li ZH; Lin Z; Duan CR; Wu TH; Xun M; Zhang Y; Zhang L; Ding YF; Yin Y
Zhongguo Dang Dai Er Ke Za Zhi; 2016 Feb; 18(2):130-5. PubMed ID: 26903059
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil for sustained remission in nephrotic syndrome.
Querfeld U; Weber LT
Pediatr Nephrol; 2018 Dec; 33(12):2253-2265. PubMed ID: 29750317
[TBL] [Abstract][Full Text] [Related]
13. Switch from cyclosporine A to mycophenolate mofetil in nephrotic children.
Ulinski T; Dubourg L; Saïd MH; Parchoux B; Ranchin B; Cochat P
Pediatr Nephrol; 2005 Apr; 20(4):482-5. PubMed ID: 15719253
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome.
Bagga A; Hari P; Moudgil A; Jordan SC
Am J Kidney Dis; 2003 Dec; 42(6):1114-20. PubMed ID: 14655181
[TBL] [Abstract][Full Text] [Related]
15. A 1-year randomized controlled study of everolimus versus mycophenolate mofetil with reduced-dose cyclosporine in maintenance heart transplant recipients.
Bara C; Dengler T; Hack MA; Ladenburger S; Lehmkuhl HB
Transplant Proc; 2013; 45(6):2387-92. PubMed ID: 23953553
[TBL] [Abstract][Full Text] [Related]
16. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen.
Schnuelle P; van der Heide JH; Tegzess A; Verburgh CA; Paul LC; van der Woude FJ; de Fijter JW
J Am Soc Nephrol; 2002 Feb; 13(2):536-543. PubMed ID: 11805185
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
Hazzan M; Labalette M; Copin MC; Glowacki F; Provôt F; Pruv FR; Noël C
J Am Soc Nephrol; 2005 Aug; 16(8):2509-16. PubMed ID: 15987748
[TBL] [Abstract][Full Text] [Related]
18. [Mycophenolate mofetil versus cyclosporine A in children with primary refractory nephrotic syndrome].
Geng HY; Ji LN; Chen CY; Tu J; Li HR; Bao R; Lin Y
Zhonghua Er Ke Za Zhi; 2018 Sep; 56(9):651-656. PubMed ID: 30180402
[No Abstract] [Full Text] [Related]
19. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
Lehmkuhl HB; Arizon J; Viganò M; Almenar L; Gerosa G; Maccherini M; Varnous S; Musumeci F; Hexham JM; Mange KC; Livi U;
Transplantation; 2009 Jul; 88(1):115-22. PubMed ID: 19584690
[TBL] [Abstract][Full Text] [Related]
20. Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up.
Argolini LM; Frontini G; Elefante E; Saccon F; Binda V; Tani C; Scotti I; Carli L; Gatto M; Esposito C; Gerosa M; Caporali R; Doria A; Messa P; Mosca M; Moroni G
J Nephrol; 2021 Apr; 34(2):389-398. PubMed ID: 32462476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
